Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

BACKGROUND: Our study aimed to compare efficacy and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Limited) versus reference adalimumab (Humira®, Abbvie Inc.) in Indian patients with active rheumatoid arthritis (RA) concomitant on methotrexate (MTX) therapy. METHODS: Patients (n = 168) wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Shubhadeep, Ghosh, Biswadip, Bandyopadhyay, Syamasis, Fatima, Firdaus, Bandi, Vamsi Krishna, Thakur, Pankaj, Reddy, Bala, Chary, Sreenivasa, Talluri, Leela, Gupta, Ajay, Kale, Amit Ramchandra, Gupta, Anil Kumar, P, Ashok Kumar, Reddy, Diwakar, Mohammed, Younus, Shekar, Soma, T, Sudheer, Goni, Vijay G., Sharma, Vishnu, Yeligod, Vishwanath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271501/
https://www.ncbi.nlm.nih.gov/pubmed/32518895
http://dx.doi.org/10.1186/s41927-020-00124-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271501/
https://www.ncbi.nlm.nih.gov/pubmed/32518895
http://dx.doi.org/10.1186/s41927-020-00124-9

Ejemplares similares